Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

Presentations


Xbrane Company Presentation April 2025

Company presentation

Presentation at Aktiespararna Life Science

April, 2025

Presenter:
Martin Åmark, CEO

 

Press Releases

08 May 2025

Xbrane Biopharma releases Interim Report January-March 2025

05 May 2025

Announcement from the annual general meeting in Xbrane Biopharma AB

04 May 2025

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2025 on May 8, 2025

14 Apr 2025

Announcement from extra general meeting in Xbrane Biopharma AB

02 Apr 2025

NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB

31 Mar 2025

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2024

20 Mar 2025

Notice of Extra General Meeting in Xbrane Biopharma AB

20 Mar 2025

Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million

20 Feb 2025

Xbrane Biopharma releases Year-end Report 2024